Join the RSV Vaccine Pref3, Recombinant group to help and get support from people like you.
RSV Vaccine Pref3, Recombinant News (Page 2)
Poll Finds Public Fears Over RSV Have Eased, Although It Remains a Threat
WEDNESDAY, Oct. 16, 2024 – Public concerns about contracting RSV (respiratory syncytial virus) have significantly declined during the past year, a new survey shows. About 1 in 4 people (26%) are now...
RSV Vaccination Effective Against Hospitalization in Patients 60 Years and Older
THURSDAY, Sept. 5, 2024 – For older adults, respiratory syncytial virus (RSV) vaccination is effective against RSV hospitalization, according to a study published online Sept. 4 in the Journal of...
RSV Infection With Inflammatory Bowel Disease Ups Risk for Hospitalization
WEDNESDAY, Aug. 28, 2024 – Adult patients with inflammatory bowel disease (IBD) and respiratory syncytial virus (RSV) infection have an increased risk for hospitalization, according to a study...
FDA Approves Expanded Age Indication for GSK’s Arexvy, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
Philadelphia, PA June 07 2024 – GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for...